Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580905 · ClinicalTrials.gov registry record · Phase 1
Role of Adenosine in the Release of VEGF and Cytokines
A Phase 1 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00580905 is a Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 8 participants.
The verdict
NCT00580905, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to extend previous observations in animal models regarding the effects of adenosine in the release of cytokines to human subjects. We intend to accomplish this in two study protocols. In the first we will infuse intravenously adenosine and measure the plasma levels of inflammatory cytokines. In the second one, we will use a microdialysis technique to infuse intradermally small amounts of adenosine and will measure skin blood flow and will take a biopsy to measure levels of mRNA for cytokines.
Interventions
- DRUG Sodium Nitroprusside
- DRUG Adenosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-06 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580905
The ClinicalTrials.gov registry entry for NCT00580905 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sodium Nitroprusside is the first listed.
NCT00580905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00580905 about?
NCT00580905 is a clinical study titled "Role of Adenosine in the Release of VEGF and Cytokines". The purpose of this study is to extend previous observations in animal models regarding the effects of adenosine in the release of cytokines to human subjects. We intend to accomplish this in two study protocols. In the first we will infuse intravenously adenosine and measure the plasma levels of in...
What is the current status of trial NCT00580905?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2007-06. Estimated completion is 2017-01.
What interventions are being tested in trial NCT00580905?
The interventions under investigation include: Sodium Nitroprusside (DRUG), Adenosine (DRUG).
Who is sponsoring clinical trial NCT00580905?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.